Abstract: Objective To investigate the effect of dapagliflozin on blood pressure and cardiac function in patients with type 2 diabetes and hypertension. Methods A total of 90 patients with type 2 diabetes and hypertension who were treated from October 2020 to April 2022 were randomly divided into dapagliflozin group and conventional group, with 45 patients in each group. The patients in the dapagliflozin group were given oral administration of 10 mg dapagliflozin once a day in addition to conventional hypoglycemic and antihypertensive drugs, and those in the control group were given conventional hypoglycemic and antihypertensive drugs alone. The two groups were compared in terms of related blood pressure and cardiac function parameters, such as systolic pressure, diastolic pressure, heart rate, left ventricular ejection fraction, and interventricular septal thickness, before treatment and after 24 weeks of treatment. Results Before treatment, there were no significant differences between the two groups in the blood pressure and cardiac function parameters such as systolic pressure, diastolic pressure, heart rate, left ventricular ejection fraction, and interventricular septal thickness (P>0.05). After treatment, compared with the conventional group, the dapagliflozin group had significantly lower systolic pressure (125.42±11.41mmHg vs 131.20±14.73 mmHg, P<0.05), diastolic pressure (75.67±9.72mmHg vs 80.11±9.87 mmHg, P<0.05), heart rate (70.28±11.94beats/min vs 75.76±12.35beats/min, P<0.05), and interventricular septal thickness (1.06±0.11cm vs1.12±0.12 cm, P<0.05) and a significantly higher left ventricular ejection fraction (65.73%±3.01% vs 62.42%±2.93%, P<0.05). Compared with the conventional group, the dapagliflozin group had a systolic pressurereduced by 5.78±3.39mmHg and a diastolic pressure reduced by 4.44±2.88mmHg; for the patients with grade I, II, and III hypertension in the dapagliflozin group, systolic pressure was reduced by 5.95±3.72 mmHg, 5.38±3.25 mmHg, and 5.91±3.14 mmHg, respectively, and diastolic pressure was reduced by 5.33±2.37mmHg,4.00±3.65mmHg, and 3.27±2.41mmHg, respectively. Conclusion Dapagliflozin can reduce blood pressure and improve cardiac function in patients with type 2 diabetes and hypertension and exerts a therapeutic effect on patients with different grades of hypertension.

Key words: Dapagliflozin, Diabetes, Hypertension, Cardiac function